Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Pilot Study of Intravenous EZN-2285 (SC-PEG E. Coli L-asparaginase) or Intravenous Oncaspar® in the Treatment of Patients With High-Risk Acute Lymphoblastic Leukemia (ALL)

NCT00671034 is registered in ClinicalTrials.gov with Children's Oncology Group as lead sponsor.

NCT NCT00671034
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00671034 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Pilot Study of Intravenous EZN-2285 (SC-PEG E. Coli L-asparaginase) or Intravenous Oncaspar® in the Treatment of Patients With High-Risk Acute Lymphoblastic Leukemia (ALL)
Lead sponsor
Children's Oncology Group
Phase
Phase 3
Overall status
Completed
Start date
July 21, 2008
Completion date
March 31, 2021
Enrollment
166 (actual)
Sites
27

Conditions

As the registry lists them; a condition with its own page is linked.

acute lymphoblastic leukemia, adult b acute lymphoblastic leukemia, childhood b acute lymphoblastic leukemia